Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262)
Fast, easy summary view of NICE guidance on 'ulcerative colitis'
NICE is unable to recommend the use in the NHS of adalimumab for the treatment of moderate to severe ulcerative colitis because no evidence submission was received from the manufacturer or sponsor of the technology.
This appraisal relates to people whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: ulcerative colitis
- None found
This page was last updated: 09 August 2013
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.